Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx a xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x č. 46/2008 Xx. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. října 2017 xxxx generální ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Přílohy X - Seznam xxxxxxxxxx látek a xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx standard Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým xxxxxx Přílohy I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx republiky xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx X x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx přestalo xxxxxx xxxxx Přílohy X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx pod č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx X a xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Seznam xxxx xxxxxx od 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX PRO ROK 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X METODY XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Specifické xxxxx" kromě xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx metod X1, X2 x M3.

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM, xxxx. xxxxxxx, LGD-4033, xxxxxxx x RAD140); xxxxxxx; xxxxxxx x zilpaterol, xxx xx x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx vztahuje x xxxxx, xxxxxx tělo xxxxxxxx přirozeně neprodukuje. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx ne x omezením pouze xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx a jejich xxxxxxxxxx (xxxx. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (FG-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx TGF - xxxx (XXX - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného opravného xxxxxxxxx. xxxx.

xxxxxx XXX; xxxxxxxxxxxxx XXX.

2. Peptidové xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (CG) x xxxxxxxxxxxx hormon (XX) a jejich xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x triptorelin, u xxxx.

2.2 Kortikotropiny a xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, xxxxxx, xxx xx x omezením xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x jeho xxxxxxx, xxxx. CJC-1295, xxxxxxxxxx x tesamorelin; xxxxxxxxxxx xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Růstové xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx s xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1) x xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx x modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- AGONISTÉ

Všichni xxxxxxxxxx i neselektivní xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx isomerů, xxxx zakázáni.

Zahrnují (xxx xx x omezením xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx v oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 40 xx/xx nebude xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx považována za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx výsledek xxx způsoben terapeutickou xxxxxx (x inhalaci) xxxxx, xxx xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx x metabolické xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx pouze xx ně.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX A MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx látky xxxx xxxxxxxx, xxxxxx xxxx xxxxx látky x xxxxxxxx chemickou strukturou x podobnými biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.

• Acetazolamid; xxxxxxxx; bumetanid; xxxxxxxxx; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx xxxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx); xxxxxxxxxx a xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu a xxxxxx podání inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx xxxxx xxxxx x té, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X XXXX X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx ně. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. To zahrnuje xxxxxx x/xxxx úpravu (xxxx. proteázami) xxxx, xxx xx s xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx celkem 100 xx za 12 xxxxx kromě xxxxxx xxxxxxxxx přijatých x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX DOPING

Z xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, vytvořených k xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 a X1 až X3 xxxxxxxxx výše

jsou Xxx Xxxxxxx zakázané x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (d-);

mezokarb;

modafinil;

norfenfluramin;

p-metylamfetamin;

prenylamin;

prolintan.

Stimulancium, xxxxx xxxx xxxxxxxx xxxxxxx x tomto odstavci, xx Specifickou látkou.

(b) Xxxxxxxxxx stimulancia.

Zahrnují (ale xx x omezením xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon a xxxx analoga (xxxx. xxxxxxxx, methedron a xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S výjimkou:

• klonidinu

• derivátů xxxxxxxxx x xxxxxxx xxxxxx místního/očního použití x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Tyto xxxxx xxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2018 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx pouze xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší než 10 mikrogramů v 1 xx xxxx.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, např. nosní, xxxx aplikace xxxx xxxx xxxxxx xxxxxxxx x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx jeho koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx kanabinoidy xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. hašiš, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx kanabinoidy, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x ostatní kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx glukokortikoidy xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx zakázané.

Včetně, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx, a xxx xx to označeno x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, a xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx potápění) (XXXX) x disciplínách xxxxxxxxxx xxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxx immersion, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis x. 36/2019 Sb. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Xx. x. x. xxx xxxxxx právním předpisem č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem jiných xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx, přijatá xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a s xxxxxxxxx xx českého xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.